Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 21, 2023
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
[ Tue, Mar 21st 2023
] - WOPRAI
Mon, March 20, 2023
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
[ Mon, Mar 20th 2023
] - WOPRAI
Ed Arce Reiterated (AKRO) at Strong Buy and Held Target at $64 on, Mar 20th, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Akero Therapeutics, Inc." (AKRO) at Strong Buy and Held Target at $64 on, Mar 20th, 2023.
Ed has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Michael Ulz of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $65 on, Friday, January 27th, 2023
